The in-depth structure/function analysis of large protein complexes, such as RNA polymerases (RNAPs), requires an experimental platform capable of assembling variants of such enzymes in large numbers in a reproducible manner under defined
Many of the enzymes involved in molecular information processing are large and complex molecular machines that are assembled from a variety of subunits. Recent technical advances in X-ray crystallography have started to yield insights into the structure of protein complexes, such as bacterial and eukaryotic RNA polymerases (RNAPs;
The availability of such recombinant
The original expression vectors for the RNA polymerase subunits A′ and B′′ from the euryarchaeal hyperthermophile
All robotic manipulations described here were carried out on either of the two Theonyx Liquid Performers (Aviso Trade GmbH), equipped with an 8-tip pipetting arm, separate gripper arm, barcode reader, vacuum manifold, microplate shaker, thermocycler, microplate reader, 96-well microdialyzer and E-Page facility (Invitrogen) and an integrated microplate centrifuge. Detailed descriptions of all robotic procedures, platform layouts and specialized hardware modifications are available from the corresponding author upon request.
Single
All procedures described subsequently were carried out on the robotic platforms at room temperature. Nine hundred microlitres of each bacterial expression culture were transferred from the 24-well growth plates to a defined position in a 2.2 ml 96-deepwell block and then lysed directly, without prior centrifugation, by the addition of a mixture of 100 μl FastBreak reagent (Promega) and 2 μl Lysonase (Novagen). The lysates were mixed extensively by repeated up- and down-pipetting and occasional vortexing on the robotic microplate shaker at 5 min intervals for a total of 30 min at room temperature. Inclusion bodies were then separated from the lysate using the robotic centrifuge (10 min at 4700 r.p.m; ∼2300
A commercially available 96-well microdialysis device (Spectrum Laboratories) was installed on top of a Hi300N magnetic stirrer (Hanna Instruments) positioned on the robotic platform. The dialyzer position is fully accessible to the pipetting and gripper arms of the robots. The perspex lid was customized for handling by the gripper (details available from the corresponding author). A peristaltic pump (Watson Marlow Sci400) was calibrated to deliver a flow-rate of 1 ml/min and switched on and off under robotic control.
The following procedures were carried out automatically without human intervention. Non-specific transcription assays (measuring the incorporation of α-32P-rUTP into acid insoluble transcripts) were set up as 50 μl reactions in a 96-well thin wall plate using reaction conditions previously described (
Structural studies of RNAPs have revealed that only a relatively small proportion of amino acid residues are likely to play any direct functional role in transcription mechanisms. These residues are typically arranged within structurally distinct domains [such as Fork Loops, Bridge Helix, Lid, Zipper, Rudder (
The RNAP from the archaeon
We started the design of the high-throughput assembly strategy by redesigning the previously used bacterial expression vectors encoding the Redesign of the bacterial expression vectors. (
The previous section described an approach capable of creating a broad range of mutations restricted to ‘functional’ residues. The resulting bacterial expression vectors encode recombinant RNAP subunits ( Flow diagram of the automated subunit purification and assembly process. See text for further details.
The need for processing a large number of expression constructs resulting from the mutagenesis strategy described above preclude the previously described methods of growth of bacterial cultures on a ‘preparative’ scale (typically 0.5–2.0 l), followed by sonication and chromatographic purification of the recombinant subunits (
Active archaeal RNAP can be reconstituted by mixing the various subunits in appropriate ratios under denaturing conditions (6 M urea), followed by the time-controlled removal of urea by dialysis against buffers containing decreasing urea concentrations ( Robotic microdialysis set-up for assembly of recombinant RNAPs. (
We demonstrate the effectiveness, reproducibility and high-throughput potential of the RNA polymerase factory strategy by showing examples of results obtained by saturation mutagenesis of a single residue of the Bridge Helix of archaeal RNAP. Briefly, the Bridge Helix is a highly conserved structure ( Saturation mutagenesis of
The ability to routinely produce and assay up to 96 recombinant RNAPs within 24 h in a highly automated manner has many advantages. The most obvious advantage is that this system is capable of testing sample numbers that exceed the capability of most human laboratory workers, especially if carried out on a continuous basis over longer periods. The increased throughput translates into an ability to screen a larger number of mutants (e.g. a library of random mutants spread over a large segment of a subunit) for particular functional properties using a variety of automated assays. Alternatively, the ability to process a substantial number of samples can be used to measure the activity of a smaller number of mutants with a high degree of accuracy by increasing the amount of information available for statistical analysis. In the examples shown here, it is clear that a comparison of various mutant and wild-type activities can be achieved with a high degree of accuracy due to the optimized and robust design of the procedure.
A slightly less obvious (but in our view equally important) key feature of the RNA polymerase factory is that the robotic work flow does not merely speed up a particular subset of steps within a long protocol, but actually encompasses the entire procedure. We have even gone as far as eliminating a rather trivial human intervention (decanting of supernatants from deep-well plate after centrifugation) by constructing a custom-built device specifically for the purpose of removing a possible source of human error (R.O.J.W., unpublished data). Using the procedure as currently implemented it is therefore possible to start with a bacterial expression strain (containing a plasmid with an easily verifiable DNA sequence) and to end up with a fully assembled RNAP and an activity result within 24 h. All the intermediate steps are carried out on robotic platforms, thus essentially eliminating the possibility of error and/or sample mix-ups. In the worst case scenario, any unexpected or questionable result can be easily checked by repeating the process and, ultimately by checking the DNA sequence of the expression clone(s) used. The high degree of reproducibility and comparability observed and documented is also due to the fact that variants located within a single subunit (such as the Bridge Helix mutants shown in
In summary, the robotic platform for the automated purification of mutant RNAP subunit variants, combined with reproducible methods for assembling them into recombinant RNAPs, provides a powerful new tool for carrying out a detailed analysis of various functional domains. The time-consuming nature of studying the effects of mutations in the context of multi-protein complexes means that conventional mutagenesis studies are typically restricted to deleting whole domains, ‘alanine scanning’ (
One of the major challenges that will need to be addressed in the foreseeable future is the development of new types of high-throughput assays capable of analyzing the functional properties of the large number of mutants that can be generated by the RNAP factory approach. For studying mutants in regions that have a direct influence on the catalytic activity of the polymerase (such as the Bridge Helix example described here), relatively simple assays capable of measuring overall nucleotide incorporation can be used to compare the activities of targeted substitutions directly with the wild-type enzyme (
Supplementary Data are available at NAR online.
The Work described here was funded by grants to R.O.J.W. (BBSRC: BB/E000975/1 and BB/D5230001/1, MRC G0501703 and Wellcome Trust: 072563/Z/03/Z and 078043/Z/05/Z). We would like to thank M. Chatzigeorgiou for his help with the preparation of some of the G825 mutants. Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.